Literature DB >> 18973402

Skin manifestations of lyme borreliosis: diagnosis and management.

Robert R Müllegger1, Martin Glatz.   

Abstract

Lyme borreliosis is a multisystem infectious disease caused by tick-transmitted spirochetes of the Borrelia burgdorferi sensu lato complex. The three characteristic cutaneous manifestations are erythema migrans, borrelial lymphocytoma, and acrodermatitis chronica atrophicans. Erythema migrans occurs in acute Lyme borreliosis, lymphocytoma is a subacute lesion, and acrodermatitis is the typical manifestation of late Lyme borreliosis. Clinical appearances of erythema migrans and lymphocytoma (when located on the ear or breast) are characteristic, whereas acrodermatitis is often confused with vascular conditions. The diagnosis of erythema migrans is made clinically. Serologic analyses often yield false-negative results and are not required for the diagnosis. However, serologic proof of the diagnosis in lymphocytoma (approximately 90% positive) and acrodermatitis (100% positive) is mandatory. Histopathologic examination often adds substantial information in patients with skin manifestations of Lyme borreliosis and is recommended in clinically (and serologically) undecided cases of erythema migrans or lymphocytoma and is obligatory in acrodermatitis. Polymerase chain reaction for Borrelia-specific DNA (rather than culture of the spirochete) and immunohistochemical investigations (lymphocytoma) are sometimes necessary adjuncts for the diagnosis. Antibacterial treatment is necessary in all patients to eliminate the spirochete, cure current disease, and prevent late sequelae. Oral doxycycline, also effective against coinfection with Anaplasma phagocytophilum, is the mainstay of therapy of cutaneous manifestations of Lyme borreliosis. Other first-line antibacterials are amoxicillin and cefuroxime axetil. Erythema migrans is treated for 2 weeks, lymphocytoma for 3-4 weeks, and acrodermatitis for at least 4 weeks.

Entities:  

Mesh:

Year:  2008        PMID: 18973402     DOI: 10.2165/0128071-200809060-00002

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  27 in total

Review 1.  Laboratory diagnosis of Lyme disease: advances and challenges.

Authors:  Adriana R Marques
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

2.  [Cutaneous manifestations of Lyme disease : Pitfalls in the serological diagnostic workup].

Authors:  M Glatz; R R Müllegger
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

3.  Borrelial pseudolymphoma of the nose.

Authors:  Mosab Tariq Mohanna; Jivko Kamarashev; Günther F L Hofbauer
Journal:  BMJ Case Rep       Date:  2015-01-07

4.  Borrelia burgdorferi Infections in the United States.

Authors:  Warren R Heymann; Dana L Ellis
Journal:  J Clin Aesthet Dermatol       Date:  2012-08

Review 5.  vls Antigenic Variation Systems of Lyme Disease Borrelia: Eluding Host Immunity through both Random, Segmental Gene Conversion and Framework Heterogeneity.

Authors:  Steven J Norris
Journal:  Microbiol Spectr       Date:  2014-12

6.  Treatment with Doxycycline of Generalized Annular Elastolytic Giant Cell Granuloma Associated with Borrelia burgdorferi Infection.

Authors:  B Tas; A Caglar; B Ozdemir
Journal:  West Indian Med J       Date:  2015-05-05       Impact factor: 0.171

Review 7.  [Differential diagnosis of leg edema].

Authors:  Christiane Stöberl
Journal:  Wien Med Wochenschr       Date:  2016-07-07

Review 8.  Clinical spectrum of Lyme disease.

Authors:  Jesus Alberto Cardenas-de la Garza; Estephania De la Cruz-Valadez; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-19       Impact factor: 3.267

Review 9.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

10.  [The variable spectrum of cutaneous Lyme borreliosis. Diagnosis and therapy].

Authors:  H Hofmann
Journal:  Hautarzt       Date:  2012-05       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.